Sarepta Therapeutics (SRPT) Upgraded at BidaskClub

BidaskClub upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a hold rating to a buy rating in a research report released on Monday morning.

A number of other equities research analysts have also weighed in on the stock. HC Wainwright initiated coverage on shares of Sarepta Therapeutics in a report on Friday, December 1st. They set a buy rating and a $75.00 price target for the company. Zacks Investment Research lowered shares of Sarepta Therapeutics from a buy rating to a hold rating in a report on Friday, December 15th. Robert W. Baird reaffirmed a buy rating and set a $101.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. Oppenheimer reaffirmed a buy rating and set a $76.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 16th. Finally, Goldman Sachs Group reaffirmed a buy rating and set a $71.00 price target on shares of Sarepta Therapeutics in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have given a buy rating to the company. Sarepta Therapeutics presently has a consensus rating of Buy and a consensus price target of $63.79.

Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at $56.75 on Monday. Sarepta Therapeutics has a 52-week low of $26.26 and a 52-week high of $57.57. The stock has a market cap of $3,670.00, a price-to-earnings ratio of -27.82 and a beta of 1.38. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 103.87% and a negative return on equity of 35.62%. The company had revenue of $45.95 million during the quarter, compared to analyst estimates of $41.29 million. During the same quarter in the prior year, the business earned ($0.95) earnings per share. research analysts forecast that Sarepta Therapeutics will post -3.11 EPS for the current fiscal year.

In other Sarepta Therapeutics news, SVP Shamim Ruff sold 10,000 shares of the stock in a transaction on Monday, November 6th. The shares were sold at an average price of $55.00, for a total transaction of $550,000.00. Following the transaction, the senior vice president now directly owns 37,045 shares in the company, valued at approximately $2,037,475. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the transaction, the director now owns 13,333 shares in the company, valued at $745,181.37. The disclosure for this sale can be found here. Insiders have sold a total of 28,167 shares of company stock worth $1,497,619 over the last quarter. 9.60% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. lifted its position in shares of Sarepta Therapeutics by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after buying an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after buying an additional 2,474 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of Sarepta Therapeutics by 140.9% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after buying an additional 2,493 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Sarepta Therapeutics in the 3rd quarter worth about $204,000. Finally, Bayesian Capital Management LP bought a new position in shares of Sarepta Therapeutics in the 2nd quarter worth about $206,000. Hedge funds and other institutional investors own 82.02% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/12/28/sarepta-therapeutics-srpt-upgraded-at-bidaskclub.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit